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with a reduction in Th1-mediated immune function and an 
increase in the activation of the Th2 immune function, indi-
cated by the augmented serum levels of IL-6 and IL-10 and 
elevated immunoglobulin E.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 In 1980, the Diagnostic and Statistical Manual of Men-
tal Disorders (DSM-III) introduced the category of so-
matoform disorders (SFD) as a provisional grouping of 
psychiatric conditions characterized by often multiple 
and variable somatic symptoms – commonly seen in gen-
eral medical practice and primary care – but defying 
medical explanation  [1] . It is clear from their high lifetime 
prevalence (4–5%) in the general population  [2, 3] , their 
high comorbidity with other conditions, their debilitat-
ing effect on patients, and their association with high lev-
els of drug use, that SFD are of great clinical and eco-
nomic importance  [4] . 
 Previous studies [e.g., ref.  5, 6 ] have reported that, rel-
ative to healthy participants, patients with SFD exhibit 
elevated levels of alexithymia. Alexithymia is a concept 
that was developed by Sifneos  [7] and is characterized by 
an inability to describe and identify feelings, by an ab-
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 Abstract 
 Objective: The aim of the present study was to investigate if 
somatoform disorders (SFD) are associated with changes in 
the normal serum levels of important interleukins, and fur-
ther, to establish if these changes are related to the presence 
and severity of alexithymia in patients with SFD.  Methods: 
Twenty-four unmedicated patients who met the Interna-
tional Classification of Diseases (ICD-10) diagnostic criteria 
for SFD completed the psychological questionnaire to assess 
alexithymia (Toronto Alexithymia Scale), symptom reporting 
(SCL-90-R) and diagnostic criteria for SFD (Screening for So-
matoform Symptoms scale). Serum concentrations of solu-
ble interleukin 2 receptor   (sIL-2 R  ), IL-4, IL-6, IL-10 and IL-12 
were determined in patients with SFD and in 9 healthy sub-
jects.  Results: In patients with SFD, serum levels of IL-6 (p  ! 
0.001), IL-10 (p = 0.047) and immunoglobulin E (p = 0.045) 
were significantly increased in comparison with healthy con-
trols. Additionally, a negative correlation was observed be-
tween the level of alexithymia (‘total’ Toronto Alexithymia 
Scale score) and the serum levels of sIL-2 R  (r = –0.538) in 
SFD.  Conclusions: Taken together, these results suggest that 
SFD, with clinically significant alexithymia, are associated 
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sence of fantasies, and by the tendency to utilize an exter-
nally focused analytical cognitive style. The concept of 
alexithymia has been examined in a variety of different 
medical, psychosomatic and psychiatric disorders  [8, 9] 
and supports the clinical impression of an association be-
tween somatization and alexithymia  [6, 10] 
 It is notable that previous studies [e.g., ref.  11 ] have re-
ported that certain cytokines can stimulate inflamma-
tory pain. It would seem plausible that the inflammatory 
response of the immune system (mediated by cytokines) 
might underlie the illness symptoms reported by patients 
with SFD. However, contrary to this notion, Rief et al.  [12] 
reported that patients with somatization syndrome actu-
ally exhibited changes in immune function that are as-
sociated with a moderate reduction in the inflammatory 
response, such as reduced levels of proinflammatory cy-
tokines such as interleukin (IL)-6 and lowered CD8 (low-
ered T-lymphocytic activity), and yet, on the other hand, 
increased IL-1 receptor antagonist with monocytic acti-
vation. This apparent inconsistency is worth of further 
study.
 As noted previously, alexithymia is related to an in-
crease in the bodily expression of emotional distress. 
With this in mind, it is plausible that high levels of alexi-
thymia would be associated with changes in immune 
function. Todarello et al.  [13, 14] reported lower counts of 
almost all lymphocyte subsets in alexithymic patients 
compared with non-alexithymic patients. Similarly, 
Dewaraja et al.  [15] reported that healthy men catego-
rized as highly alexithymic exhibited decreased cytotox-
ic lymphocyte counts (for natural killer subset CD57–
CD16+ cells and killer effective T cell CD8+CD11a+ 
cells). In a recent study, Corcos et al.  [16] examined alex-
ithymia, mood (depression and anxiety) and serum levels 
of the different cytokines in a group of 17 healthy women 
and found a positive correlation between the participants’ 
scores on the Toronto Alexithymia Scale (TAS) and their 
serum levels of IL-4. Moreover, Kelly-Welch et al.  [17] re-
ported that the deregulation of anti-inflammatory cyto-
kines such as IL-4 may lead to a disturbance of the type 
1/type 2 cytokine balance. A major consequence of this 
cytokine imbalance is an increase in Th2 response, with 
a resultant increase in immunoglobulin E (IgE) antibody 
synthesis leading to an inflammatory response in the 
body. 
 As there have only been a few studies examining acti-
vation of the inflammatory response system and changes 
in immunological variables in SFD  [17, 18] , and similarly, 
as there has been relatively little research addressing the 
effects of alexithymia on the immune function [e.g., ref. 
 16, 19 ], it is important to extend this research in order to 
develop our understanding of the role of the immune re-
sponse in SFD. Considering that patients with SFD have 
been shown to exhibit elevated levels of alexithymia  [5, 6] , 
it is plausible that the observed changes in the immune 
function of patients with SFD might relate to differences 
in concomitant alexithymia. However, as yet, there has 
been no study that has examined the relationship be-
tween alexithymia and cytokine production in patients 
with SFD. Therefore, the aim of the present study was to 
conduct such an investigation.
 In the present study, serum levels of key interleukins , 
i.e. IL-4, IL-6, IL-10, IL-12 and soluble IL-2 receptor   
(sIL-2 R  ), were systematically examined in a group of 
patients with SFD and a group of healthy controls. The 
presence and severity of alexithymia in patients with SFD 
was also established using the TAS. In line with previous 
work, we predicted a higher prevalence of alexithymia in 
SFD compared with the population norms  [20, 21] . Sec-
ond, it was predicted that there would be changes in the 
serum levels of the key cytokines in the patients with SFD 
relative to the healthy controls. Furthermore, it was ex-
pected that these changes in serum levels would be sig-
nificantly correlated with the patients’ alexithymia (TAS-
26) scores.
 Methods 
 Participants 
 Twenty-four patients (16 females, 8 males) meeting the Inter-
national Classification of Diseases (ICD-10) criteria for SFD and 
9 healthy controls (4 females, 5 males) took part in the present 
study. Ten of the SFD patients were diagnosed with somatization 
disorder (F45.0), 13 with somatoform autonomic dysfunction 
(F45.3), and 1 with persistent somatoform pain disorder (F45.4). 
The characteristics of the patients are presented in  table 1 . The 
patients with SFD were recruited from an outpatient clinic of the 
Department of Medicine (Munich University), where they had 
been referred for a diagnostic interview and counselling in the 
psychiatric and psychosomatic field. Inclusion criteria for the pa-
tient group were the presence of SFD diagnosed according to the 
ICD-10 criteria. The diagnosis was established through a clinical 
interview conducted by a trained psychiatrist (P.G.F.), who per-
formed extensive physical and psychological assessment of the 
patients, including checking for the signs and symptoms of SFD 
as outlined in the diagnostic criteria cited in the ICD-10  [22] . A 
further aid to the diagnosis of SFD was that the participants fulfill 
the criteria on the Screening for Somatoform Symptoms (SOMS) 
questionnaire  [23] . Physical conditions (e.g., angina) that may 
have explained the patients’ symptoms had been excluded prior 
to referral following extensive inpatient or outpatient investiga-
tion at the Department of Medicine or in general practice. The 
presence of an acute or chronic infection or a recent history of an 
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infectious disease (e.g., influenza) within the past 4 weeks was a 
further exclusion criterion. Exclusion criteria for the patient 
group were also the presence of medical disorders (e.g., neo-
plasms, autoimmune, cardiac, pulmonary or endocrine diseases), 
severe mental illnesses, such as schizophrenia, schizoaffective 
disorder, bipolar disorder, substance abuse disorders, major de-
pression, co-medication with benzodiazepines or other psycho-
tropic medication during the past 4 weeks. Thus, in principle, the 
patients were drug free in order to minimize pharmacological in-
fluence, if possible. It should be noted that there was a high level 
of psychiatric comorbidity in the patient sample, as 23 of the 24 
patients exhibited significant symptoms of other psychiatric dis-
orders. The most common comorbid disorder (n = 17) was dys-
thymia (F34.1). Depressive reaction (F43.2) was the next most 
common disorder (n = 4). There was also 1 case of an anxiety dis-
order (F41.1) and 1 case of neurasthenia (F48.0). The participants 
(n = 9) in the healthy control group were recruited from hospital 
employees and from the student population at the University of 
Munich. The 9 healthy volunteers were included following a med-
ical examination (medical and psychiatric history) and the estab-
lishment of normal laboratory parameters (including normal val-
ues of haematological screening, blood chemistry with glucose, 
total protein, total bilirubin, liver enzymes, electrolytes, creati-
nine, urea, uric acid, cholesterol, triglycerides, semiquantitative 
urinalysis, and thyroid hormones, C-reactive protein, luteinizing 
hormone, folliculo-stimulating hormone, prolactin, progester-
one, oestrogens, testosterone). They were in good general health 
and there was no evidence of a serious medical disease or a psy-
chiatric disorder in any of the participants in the control group. 
As the controls were screened for psychiatric disorder prior to in-
clusion in the study, it was not considered necessary to conduct 
the same detailed psychological measurement that was conducted 
on the patients with SFD. In common with the (SFD) patient 
group, regular drug intake, the presence of acute or chronic infec-
tion and/or a recent history of an infectious disease within the 
past 4 weeks were the exclusion criteria. Female subjects were not 
taking birth control pills and had regular menstrual cycles, but 
the actual menstrual status was not considered. In both groups, 
IgE serum levels were determined in a certified routine labora-
tory. The study protocol was approved by the Ethical Committee 
of the University of Munich in accordance with the Declaration 
of Helsinki. Full written informed consent was obtained from 
each participant before study inclusion. 
 Materials and Procedure 
 Subjects fulfilling the inclusion criteria were invited to par-
ticipate in the study and were assessed using a number of psycho-
logical measures. Blood serum levels of the different interleukins 
were also established for the 2 participant groups. 
 Questionnaires and Measures 
 The original version of TAS was developed by Taylor et al.  [24] 
as a standardized self-assessment questionnaire to measure alex-
ithymia. The authorized German version (TAS-26) has subse-
quently been developed by Kupfer et al.  [20, 21] , which consists of 
26 items that can be rated on a 5-point Likert scale and was used 
in our study to assess the presence and severity of alexithymia in 
the participants. This measure includes 26 items that generate 
scores on 3 dimensions: ‘difficulty identifying feelings’, ‘difficul-
ty describing feelings’ and ‘externally orientated thinking’. The 
German version was validated with a representative population 
sample (n = 2,084) and shows adequate internal consistencies 
ranging between r = 0.67 and r = 0.84. Scores over raw value 54 
(T score 61) on the TAS-26 are taken to indicate significant alex-
ithymia, and this cut-off point is used to distinguish alexithymic 
and non-alexithymic individuals. 
 The SOMS  [23] is a self-rating questionnaire by which 53 phys-
ical symptoms are investigated. The questionnaire includes all 33 
physical complaints from the DSM-IV and the symptoms from 
ICD-10. Adding the number of positively answered symptoms al-
lows computation of the ‘somatization index’ (ranging from 0 to 
33 points), which was also used in our study. The number of self-
rated somatization symptoms correlated with the number ob-
tained by interview (r = 0.75), thus confirming the high validity 
of the SOMS.
 The 90-item version of the Symptom Checklist-90 Revise 
(SCL-90-R)  [25] is a widely used self-report questionnaire (90 
items, 5-point Likert scale). The SCL-90-R asks for somatic and 
psychic complaints.
 The 21-item Hamilton Rating Scale for Depression (HAMD) 
 [26] was included in the present study to provide an observer-
rated measure of depression severity. This assessment was con-
ducted by a fully trained psychiatrist (P.G.F). The 21-item Beck 
Depression Inventor (BDI) scale  [27] was utilized in the present 
study to provide an index of self-rated depression severity. 
 Assessment of Serum Levels of Interleukins 
 Serum samples were centrifuged, and serum was frozen in al-
iquots at –20  ° C. Aliquots were defrosted, a standard curve of cy-
tokines was established, and serum levels of the different interleu-
kins were calculated (pg/ml) by using the Quantikine  (sIL-2 R  ) 
or the Quantikine high-sensitivity (IL-4, IL-6, IL-10, IL-12) en-
zyme-linked immunosorbent assay (ELISA) kit from R&D Sys-
tems (Minneapolis, Minn., USA). Means of duplicate samples 
were used for calculation of the serum levels. The procedure was 
performed as recommended by the manufacturer. Infectious and 
inflammatory diseases, which could interfere with serum cyto-
Table 1. Demographic and clinical characteristics of patients with 
SFD
Variable Patients with
SFD (n = 24)
Age, years 37.1 (10.4)
Gender, male/female 8/16
Somatization severity score (SOMS) 16.3 (10.5)
Global severity index (SCL-90-R) 69.3 (12.1)
HAMD 13.4 (4.2)
BDI 18.8 (9.6)
TAS-26 (T score)
Total score 55.7 (8.2)
Factor 1 ‘difficulty identifying feelings’ 63.8 (12.1)
Factor 2 ‘difficulty describing feelings’ 53.5 (8.7)
Factor 3 ‘externally orientated thinking’ 47.4 (12.6)
Figures in parentheses are SD.
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kine detection, were excluded by C-reactive protein, and the 
erythrocyte sedimentation rate was within normal limits in all 
patients. Furthermore, a hormone screen was performed to ex-
clude endocrine diseases as cause of altered serum cytokine levels. 
There were 2 considerations when selecting the panel of cytokines 
investigated in the present study: first, we wanted to broadly cov-
er the different immune functions, namely the Th1/Th2 dichoto-
my and the subsequent T/B cell activation that triggers cellular 
versus humoral immunity. IL-2 and IL-6 reflect general immune 
activation, whereas IL-4 is a cytokine of the Th2 immunity, which 
inhibits T effector cells and activates B cell immunity and here-
with the humeral antibody response. IL-10 is produced by T cells 
and regulates Th2 differentiation. IL-12 is a member of the Th1 
immunity that mediates T-cell-mediated effector mechanisms. 
Second, serum levels must be detectable in physically healthy hu-
mans. Interferon-  and tumor necrosis factor-  (Th1), IL-5 and 
IL-13 (Th2), and IL-1  and IL-2 (generally proinflammatory) are 
not detectable in healthy volunteers. Although IL-4 is generally 
not detectable, we included this cytokine to refer to the publica-
tion by Corcos et al.  [16] . sIL-2 R  was chosen instead of IL-2, as 
it has been shown in several investigations that sIL-2 R  corre-
lates with increased B and T cell activation and immune system 
activation, e.g., rheumatoid arthritis or systemic lupus erythema-
tosis  [28] . 
 Data Analysis 
 All data were analysed by SPSS for Windows© 11.5. The data 
were examined for normal distribution using the Shapiro-Wilk 
test. Since most parameters were not normally distributed, non-
parametric Mann-Whitney U tests were performed to establish if 
any observed differences between the 2 groups in serum levels of 
the different interleukins were significant. Mann-Whitney U 
tests and Fisher’s exact test were performed to test for significance 
of group differences for the parameters age, education and IgE. 
Interactions between the serum levels of the interleukins and par-
ticipants’ alexithymia (indexed by the participants’ scores on the 
TAS-26) and depression scores (BDI, HAMD) were calculated 
with the non-parametric Spearman’s coefficient . In order to elu-
cidate the relationship between serum levels of the interleukins, 
participant characteristics and alexithymia, a forward stepwise 
multiple regression was conducted with serum levels (sIL-2 R  , 
IL-4, IL-6, IL-10, IL-12), age and scores on BDI, HAMD, all SCL-
90-R scales entered as predictor variables, and participants’ TAS-
26 scores entered as the dependent variable. 
 Results 
 Participant Characteristics and Psychopathology 
 Analysis of the participant characteristics ( table 1 ) re-
vealed that the age of the patients with SFD (mean 37.1 
years, SD 10.4) did not differ significantly from the age of 
the controls (mean 32.2 years, SD 6.5; p = 0.179). A high-
er educational level was indicated in 45.8% of the patients 
and 55.6% of the controls (p = 0.123). Analysis of the par-
ticipants’ scores on the SOMS revealed that the patients 
with SFD exhibited elevated scores (mean 16.3, SD 10.5), 
indicating that these patients showed signs of moderate 
to severe somatization. A HAMD score of 13.4 (SD 4.2) 
demonstrated only moderate depression severity. Analy-
sis of the participants’ subjective general psychiatric 
symptomatology (indexed by the participants’ scores on 
the SCL) revealed that the patients exhibited an elevated 
global severity index (mean 69.3, SD 12.1). Our patients 
exceeded the mean value (50) on all scales of SCL-90-R 
for somatization, obsessive compulsiveness, social inse-
curity, depression, anxiety, aggression, phobic anxiety, 
paranoid ideation, and psychoticism (data not shown).
 Assessment of Alexithymia 
 Analysis of the participants’ alexithymia (TAS-26) 
scores ( table 1 ) revealed that the patients with SFD showed 
a TAS ‘total’ score (T score) of 55.7 (SD 8.2). Further in-
spection revealed that the patients scored significantly 
higher on the factor 1 of TAS (‘difficulty identifying feel-
ings’) with 63.8 (SD 12.1) over the cut-off T score  [20, 21] . 
However, the patients’ scores on factor 2 of TAS (‘diffi-
culty describing feelings’) with 53.5 (SD = 8.7) and on 
factor 3 ‘externally orientated thinking’ with 47.4 (SD 
12.6) were not in the alexithymic range. 
 Interleukins and Alexithymia 
 Correlational analysis ( table 2 ) revealed that sIL-2 R  
was significantly negatively related to the patients’ total 
TAS scores [r s (24) = –0.54, p  ! 0.05]. This analysis also 
revealed a significant negative correlation between IL-4 
serum levels and the patients’ total TAS-26 scores 
[r s (24) = –0.49, p  ! 0.05]. There were no other significant 
relationships revealed by this analysis.
 In order to further elucidate the nature of these rela-
tionships, a forward stepwise linear regression was con-
ducted and revealed a significant model with sIL-2 R  
entered as the only significant predictor of the patients’ 
alexithymia scores (p = 0.041) that accounted for 20% 
(16%) of the variance in the patients’ alexithymia (TAS-
26) scores (R 2 = 0.201, R 2 adjusted = 0.159; F 1, 20 = 4.8; 
p  ! 0.05).
 Assessment of Interleukin Serum Levels 
 Analysis of the serum levels of the different interleu-
kins detected for the patients with SFD and healthy con-
trols ( table 3 ) revealed that the level of IL-10 was signifi-
cantly augmented in the patients (mean 2.52 pg/ml, SD 
2.7) in comparison with the control group (mean 0.65 
pg/ml, SD 1.3; U = 1.99, with 24 patients and 9 controls; 
p  ! 0.05). Furthermore, patients with SFD exhibited ele-
vated levels of IL-6 (mean 2.61 pg/ml, SD 1.4) relative to 
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the controls (mean 1.01 pg/ml, SD 0.5; U = 3.61, with 24 
patients and 9 controls; p  ! 0.001). On the other hand, the 
2 groups did not differ significantly in terms of the serum 
levels of IL-4, IL-12 and sIL-2 R  (all tests p  1 0.05). IL-4 
levels were not detectable in the majority of probes, i.e. 
only in 7 patients and in 3 controls.
 Depression and Interleukins 
 Inspection of the patients’ depression scores only in-
dicated moderate levels of depression, with 13.4 on the 
HAMD (SD 4.2) and 18.8 on the BDI (SD 9.6). Impor-
tantly, correlational analyses demonstrated no signifi-
cant relationships between the patients’ depression scores 
(HAMD and BDI) and the observed serum levels of the 
interleukins (data not shown). 
 Immunoglobulin (IgE) 
 Since the above described results suggested enhanced 
Th2 immunity in SFD patients, we determined the ef-
fector immunoglobulin in the serum. Accordingly, IgE 
serum levels were found to be significantly (p = 0.045) 
increased in SFD patients (mean 234 U/ml, SD 278)
in comparison with healthy controls (mean 53 U/ml,
SD 56.8).
 Discussion 
 As expected, we found a higher prevalence of alexi-
thymia in patients with SFD, regarding the TAS factor 1 
‘difficulty identifying feelings’. This is in agreement with 
empirical findings which support a positive association 
between somatization and alexithymia  [6, 29] . Consistent 
with our hypothesis, we found augmented IL-6 and IL-10 
in the patients with SFD relative to healthy controls. This 
pattern is interesting and suggests that the immune re-
sponse in SFD is complex. IL-6 is a pro-inflammatory 
cytokine that is released in response to trauma or inflam-
mation, and IL-10 is a regulatory cytokine that suppress-
es Th1 response and induces Th2 response in general im-
mune activation  [30] . However, these cytokines are not 
specific enough to discriminate between Th1 and Th2 
predominance. Therefore, the significantly elevated IgE 
levels in our patients with SFD strongly support the hy-
pothesis of an enhanced Th2-mediated immunity. 
 The finding of augmented IL-6 is inconsistent with 
previous studies addressing immune response to SFD. 
For example, Rief et al.  [12] reported significantly lower 
serum levels of IL-6 in patients with somatization syn-
drome. It is plausible that the elevated IL-6 levels in the 
present study were a consequence of concurrent depres-
sion in our patients with SFD, because 87.5% exhibited 
comorbid depressive symptoms. Nevertheless, in previ-
ous studies [e.g., ref.  31, 32 ], higher IL-6 levels were found 
in depressed patients. However, in the present study, the 
lack of a significant correlation between self- or clinician-
Table 2. Relationships between alexithymia (TAS-26 scores) and serum levels of the different interleukins in the patients with SFD
(n = 24)
Type of interleukin
sIL-2 R IL-4 IL-6 IL-10 IL-12
TAS, factor 1 ‘difficulty identifying feelings’ rs = –0.256 rs = 0.025 rs = –0.204 rs = –0.083 rs = 0.014
TAS, factor 2 ‘difficulty describing feelings’ rs = –0.306 rs = –0.071 rs = 0.000 rs = 0.133 rs = –0.088
TAS, factor 3 ‘externally orientated thinking’ rs = –0.027 rs = –0.248 rs = 0.202 rs = –0.05 rs = 0.346
TAS ‘total’ score rs = –0.538* rs = –0.491* rs = 0.162 rs = –0.031 rs = 0.019
* p < 0.05; correlations computed using Spearman’s tests.
Table 3. Mean serum levels (pg/ml) of the different interleukins 
for SFD patients and healthy controls
Type of
interleukin
Patients with SFD
(n = 24)
Healthy controls
(n = 9)
p value
sIL-2 R 884.1 (206.4) 898.5 (208.4) 0.894
IL-4 0.004 (0.01) 0.32 (0.8) 0.185
IL-6 2.61 (1.4) 1.01 (0.5) 0.000*
IL-10 2.52 (2.7) 0.65 (1.3) 0.047*
IL-12 0.27 (0.1) 0.71 (1.4) 0.329
Figures in parentheses are SD. Significance determined using 
Mann-Whitney U tests with adjusted  for multiple comparisons; 
* p < 0.05.
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rated depression severity and serum levels of the interleu-
kins does not fit with this proposal. 
 In contrast to our hypothesis, the observed changes in 
IL-6 and IL-10 were not significantly related to the par-
ticipants’ alexithymia scores. However, it should be noted 
that serum levels of sIL-2 R  were negatively related to 
the patients’ alexithymia scores; thus, high levels of alex-
ithymia were associated with a reduction in the levels of 
these interleukins. Although the function of the sIL-2 R  
is unclear, increased levels of the sIL-2 R  in biological 
fluids have been reported to correlate with increased im-
mune system activation  [33, 34] . In our patients with SFD, 
serum levels of sIL-2 R  were negatively correlated with 
alexithymia. A plausible explanation of these results is 
that patients with more alexithymic features may be suf-
fering from (unnoticed) chronic stress reaction with con-
comitant activation of Th2 response and an associated 
reduction in Th1-mediated immunity (indicated by the 
reduction in sIL-2 R  ). This proposal is consistent with 
the hypothesis of Guilbaud et al.  [19] , who reported that 
alexithymic individuals may suffer from unnoticed 
chronic stress with associated changes in endocrine and 
immune functions, such that the Th1/Th2 balance is 
shifted towards Th2-dominant immunity (augmented 
IgE antibody synthesis), accompanied by a lowered cell-
mediated (Th1) immune response. The negative relation-
ship between alexithymia and IL-4 serum levels, ob-
served in the present study, is inconsistent with the find-
ings of Corcos et al.  [16] , who reported a positive 
association in a group of 17 healthy females, between se-
rum levels of IL-4 and scores on the TAS factor 1 ‘diffi-
culty identifying feelings’. However, in our study, IL-4 
levels were not detectable in the majority of the patients, 
and therefore, the results must be interpreted with care 
despite the statistical significance. In comparison with 
Corcos et al.  [16] , who only included females, we investi-
gated both genders in SFD in relation to alexithymia and 
interleukins. The effects are to be considered highly sig-
nificant, without however regarding the gender effect in 
our study. It is valuable to examine the question of gender 
in further studies, because most studies in general popu-
lation samples have found that men show more alexi-
thymia than women  [35, 36] ; however, other studies have 
observed no association between alexithymia and gender 
 [37] . 
 In summary, the findings of the present study are in 
agreement with the stress-alexithymia hypothesis  [38] , 
which posits that alexithymia is related to sympathetic 
hyperactivity. In line with this suggestion, Friedlander et 
al.  [39] proposed that SFD may result from the alexithy-
mic inability to differentiate and elaborate affect, which 
gives rise to physiological arousal and a negative subjec-
tive state. This decoupling between subjective and physi-
ological arousal may increase the risk for alexithymic in-
dividuals of stress-related illnesses  [40] . Furthermore, 
there is evidence that physical and psychological stress-
ors can provoke transient increases in proinflammatory 
interleukins  [41–43] . On the other hand, it is of interest 
that in recent research  [44, 45] , there have been indica-
tions that alexithymia might be associated with decreased 
basal activity of the hypothalamic-pituitary-adrenal axis. 
In contrast, in a recent study  [46] , a positive relationship 
between alexithymia and high cortisol levels was found. 
Other authors  [47–49] even discussed hypocortisolism as 
a biological marker of stress-related disorders such as 
chronic fatigue syndrome or other idiopathic syndromes, 
like SFD. Thus, further studies have to focus on investi-
gating neuroendocrine parameters in addition to immu-
nology variables to clarify possible associations. 
 Some questions remain unanswered. For instance, in-
creased serum markers of inflammation have been found 
in obese subjects  [50, 51] , although the mechanism of ac-
tion and the primary event are unclear. With respect to 
our study, obesity may strengthen an otherwise activated 
inflammatory process  [52] . Alternatively, obesity may be 
the result of a psychological illness and may herewith in-
fluence immune responses. We have not assessed these 
parameters, but upcoming studies comparing alexithy-
mic patients with healthy controls should include the 
evaluation of the body mass index and, if possible, the fat 
distribution pattern as well. Furthermore, although the 
healthy volunteers were routinely checked for any somat-
ic disease or psychiatric disorder, they were not thor-
oughly assessed according to psychology measures and a 
structured clinical interview according to ICD-10, as the 
patient group had been. In addition, the control sample 
was relatively small, which may have influenced our abil-
ity to detect subtle changes in interleukin levels. How-
ever, most studies investigating immunological variables 
have used patients that have been treated with medica-
tion at the time of testing. This is important because in-
creases  in  the  circulating  levels   of   tumor   necrosis   fac-
tor-  , IL-6 and other inflammatory cytokines have been 
reported in response to psychotropic drugs, antipsychot-
ics, antidepressants, and mood stabilizers  [53–55] . Find-
ing patients with SFD who are not currently medicated is 
difficult; thus, a major strength of our study was that 
none of our sample (patients and control group) were on 
medication at the time of testing. 
 Alexithymia and Interleukin Variations 
in Somatoform Disorder 
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 In summary, our study represents the first investiga-
tion of the relationship between alexithymic symptoms 
in SFD and changes of important cytokines. Further 
studies would be valuable to replicate our results and to 
evaluate the influence of immune balance in extended 
samples of patients with SFD and possibly later in thera-
peutic interventions.
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